News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
1don MSN
Ga., slammed the U.S. Food and Drug Administration's move to give the green light to Moderna's mNEXSPIKE COVID-19 vaccine."Not MAHA at all!!!," the congresswoman wrote in a post on X, using the ...
Moderna stock jumped 4.93% to $27.87 in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine requiring only one-fifth the dose of the company's current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback